April 20, 2014 10:37 PM ET

Life Sciences Tools and Services

Company Overview of BioScale, Inc.

Company Overview

BioScale, Inc., a life science tool company, develops, manufactures, and promotes protein measurement tools to accelerate drug discovery, development, and production of biological and pharmaceutical products. The company offers acoustic membrane microparticle technology based ViBE protein analysis platform that allows design and configuration of protein assays for highly-sensitive detection and quantitation of proteins in biological samples used in pre-clinical and clinical research, bioprocessing, patient point-of-care, and personalized medicine applications. Its ViBE platform comprises ViBE BioAnalyzer, a research tool for assay development or small to medium size studies; and ViBE Worksta...

4 Maguire Road

Lexington, MA 02421

United States

Founded in 2002

Phone:

781-430-6800

Fax:

781-430-6801

Key Executives for BioScale, Inc.

Co-Founder
Co-Founder and Director
Age: 58
Vice President of Finance & Administration
Chief Technology Officer
Director of Corporate and Marketing Communications
Compensation as of Fiscal Year 2013.

BioScale, Inc. Key Developments

BioScale, Inc. Presents at Sachs Annual Biotech in Europe Investor Forum, Oct-01-2013 12:00 PM

BioScale, Inc. Presents at Sachs Annual Biotech in Europe Investor Forum, Oct-01-2013 12:00 PM. Venue: Hilton, Zurich Airport Hotel, Hohenbuehlstrasse 10, Opfikon-Glattbrugg 8152, Zurich, Switzerland.

BioScale, Inc. Presents at EBD Group AG's Biotech showcase 2013, Jan-07-2013 09:30 AM

BioScale, Inc. Presents at EBD Group AG's Biotech showcase 2013, Jan-07-2013 09:30 AM. Venue: Parc 55 Wyndham Union Square Hotel, San Francisco, California, United States. Speakers: Mark Lundstrom, Co-Founder, Chief Executive Officer, President and Director.

BioScale, Inc. Presents Comparative Analysis of in Vitro and in Vivo Kinase Activity and Expression Using the AMMP(R) Assay at the European Association of Cancer Research Meeting

BioScale, Inc. presented findings of recently completed research studies on phospho-protein analysis of the in vitro and in vivo kinase expression in the MAP kinase pathway at the 22nd Biennial European Association for Cancer Research (EACR) Congress, held in Barcelona, Spain, July 7-10, 2012. The presentation entitled "Comparative Analysis of in vivo and in vitro Expression of Kinases in the MAPK Kinase Pathway" was presented by Lee Anne Beausang, Ph.D. Senior Assay Development Scientist. The studies reported here utilized non-optical, AMMP(R) (acoustic membrane microparticle) technology to assess and quantify the activation states of several implicated kinases: EGFR, p38, and AKT in their native state from multiple cancer cell lines. Phosphorylation states of kinases from multiple human tumor cell line lysates, with or without mitogenic stimulation, were compared with lysates prepared from xenografted tumors derived from the same cell lines. The results indicated successful measurement of native phospho- and total kinase biomarkers in xenografted tumors and the cell lines from which they were derived with nearly identical levels - a novel result that had not previously encountered in published literature. The relationship between total protein and cell numbers allows for an assessment of sensitivity based on cell numbers (<1000 cells/measurement). This is advantageous when analyzing tumor biopsy samples where cell numbers are generally low, and allows for more screening options with limited sample. The numbers of cells required for the determinations are consistent with those available from fine needle aspiration of in situ tumors, thus permitting the potential for "finger-printing" a specific tumor and evaluating multiple chemotherapeutic regimens against the tumor. These studies have also demonstrated the feasibility of quantifying biomarker analytes in the complex matrices of cell and tumor lysates with significant correlation between quantitated biomarker and the AMMP signal. The quantitation (mass/volume) of biomarker proteins using the AMMP assay format permits the elucidation of the phospho- to total kinase ratios observed in both tumor cell lines and xenografted tumors derived from them. These ratios appear to be characteristic of the individual cell lines, and will provide medicinal chemists additional criteria from which to define appropriate therapeutic targets for drug discovery.

Similar Private Companies By Industry

Company Name Region
Knopp Neurosciences, Inc. United States
Lifecycle Sciences Group United States
Kirkegaard & Perry Laboratories, Inc. United States
Dynex Technologies, Inc. United States
Proteonomix Regenerative Translational Medicine Institute, Inc. United States

Recent Private Companies Transactions

Type
Date
Target
Private Placement
June 21, 2013
--
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
NYC2012, Inc. United States
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
Rush University United States
Greater Houston Partnership United States

Post a JobJobs

View all jobs

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact BioScale, Inc., please visit www.bioscale.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.